AR and Familial prostate cancer: Androgen receptor signaling appears to be a primary driver of prostate cancer progression, with the majority of prostate cancer deaths occurring from androgen-receptor-positive, castrate-resistant prostate cancer, making the MPC an attractive therapeutic target for this prostate cancer subtype.